Oct 14, 2026
This is the free newsletter you subscribed to. Please enjoy!
Oct 12, 2026
Five weeks after launch, the Ackman Oxman Institute helped lead a $250 million round for Precision Neuroscience. The mitochondria treatment that inspired it remains a single patient whose benefit faded within weeks.
A Science Advances study out September 17 traces part of the age-related drop in NAD, the molecule behind a booming supplement market, to an enzyme inside blood vessel walls. The mice were engineered to age fast, which limits what it means for you.
*A new study in Aging Cell cut growth hormone signaling in mice at the human equivalent of about age 40. Females gained 8% in median lifespan, and males maintained more strength, but the gains were smaller than in lifelong models.
A Nature Medicine paper out September 22 finds the change tracks hormones more than birthdays. The link to dementia is real but modest, and there is nothing to test for yet.
A Finnish study that followed 2,690 men until nearly all of them had died, published in late August, answers the question every healthy-habits lecture skips: do the extra years feel good?
Oct 7, 2026
Oct 5, 2026
Two studies published September 22, and an advisory vote on September 23, give the clearest picture yet of what one blood draw can and cannot tell you about cancer.
It is the first time a pig organ has carried a patient all the way to a human transplant, and formal trials for people in their 50s and 60s are now starting
When the mutations were confined to heart muscle cells, pumping strength fell by about 25 percent by 9 months and kept sliding with age.
A Nature study traced the inflammation to a mitochondrial citrate pump, and blocking it for three months delayed frailty without killing a single cell.
A 7,504-person German study found that these diets barely overlapped on the plate yet pointed to the same biological pathways.
Sep 30, 2026
Sep 29, 2026
The heart benefit is real. The independent-years benefit is not
A 154,000-person study links accelerated aging to early-onset cancer in adults under 55.
The first lifespan study of a GLP-1 drug matched calorie restriction and beat it on memory and glucose
A Yale-led analysis of the only long-term calorie-restriction trial in humans identifies the switch that quiets inflammaging
The two-year LatAm-FINGERS trial delivered a 55 percent bigger cognitive gain than flexible guidance.
Sep 23, 2026
Sep 22, 2026
A randomized trial in 148 adults aged 70 to 85 found a dose-dependent gain in walking endurance, and no serious side effects were attributed to the treatment
The first mitochondrial transplant into human eyes has now been performed, and the report describing it went up last month without peer review
A just-published Nature Aging study isolates valine as the lever, and the benefit splits sharply by sex
New research says this five-part measure predicts memory trouble years before it shows up
It is a real scientific first. It is also an 18-person safety study in eye disease, with no placebo and no results expected before 2027.
Sep 15, 2026
Twenty-four randomized trials say they do reduce pain and improve function. The same analysis says nobody can yet tell you which version to buy.
